The World Health Organization’s Phase II/III SOLIDARITY trial for COVID-19 is currently the world’s largest randomized clinical trial for the…
On October 16, Amylyx announced that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed potential to prolong patient survival and slow rapid disease progression in ALS patients. The results…
Since early March, more than 500 companies have publicly announced clinical trial disruptions, both planned and ongoing, due to the Covid-19 pandemic. Many companies have delayed the initiation of planned…
On the 9th of October, Alkermes announced positive voting from the joint meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee…
With the persisting global devastation of COVID-19, researchers worldwide are moving at a rapid pace to identify and develop viable vaccine candidates. Second waves of COVID-19 worldwide will coincide with…
by Reynald Castaneda in London. AstraZeneca’s Covid-19 vaccine AZD1222 splits experts as to whether its trials restarted too quickly on the heels of a second volunteer having a neurological event.…
by Manasi Vaidya in New York and Reynald Castaneda in London. Eli Lilly’s and Regeneron Pharmaceuticals’ bids to secure an FDA Emergency Use Authorization (EUA) for their respective monoclonal antibodies (mAbs) caused caution…